Xvivo Perfusion
XVIVO Perfusion is a Swedish medical technology company focused on organ preservation, assessment, and recovery for transplantation. Its business spans thoracic and abdominal transplantation technologies, organ recovery services, and digital communication tools used by transplant teams and hospitals across multiple markets.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueProducts for lung and heart transplantation, including preservation and machine perfusion systems.
Liver and kidney perfusion technologies used to preserve and assess abdominal organs.
Clinical recovery services for donor organs, including coordination and transport support.
Subscription-based communication software for transplant-clinic coordination.
Customers
XVIVO sells primarily to transplant centers, hospitals, organ procurement organizations, and clinical teams involved in organ recovery and transplantation. Customers buy its products and services to expand transplant programs, improve organ utilization, and support more efficient coordination across donor and recipient pathways.
Buy perfusion systems and disposables for lung, liver, kidney, and heart transplantation to improve organ assessment and utilization.
Use organ recovery services and related clinical support to manage donor organs and transplant workflows.
Coordinate donor organ recovery and transport, often alongside XVIVO service teams and logistics partners.
Use FlowHawk and related workflow tools to coordinate communication across donor, recipient, and recovery teams.
Strategy
XVIVO’s strategy centers on expanding machine perfusion, organ recovery services, and evidence-backed technologies across thoracic and abdominal transplantation. The company is also building a broader commercial platform through new product launches, regulatory approvals, and recurring service and software revenue.
Installed systems drive recurring disposable sales and deepen customer relationships.
Organ recovery services create recurring revenue and embed XVIVO in transplant workflows.
New indications enlarge the addressable market and diversify the product portfolio.
Transplant products require strong clinical data and regulatory clearance to scale.
Geography
XVIVO is headquartered in Gothenburg, Sweden and operates through subsidiaries in the US, Netherlands, Italy, France, Brazil, Australia, and China. Its revenue base is international, with reported sales concentrated in EMEA for abdominal products and meaningful activity in North and South America for services and selected product lines.
Risks
XVIVO is exposed to regulatory, clinical, and adoption risk because its products operate in a highly controlled transplant environment and often require clinical evidence before broad commercialization. It also faces currency, financing, and operational risks, along with healthcare-system budget pressure, trade barriers, and the possibility that transplant volumes or new treatment adoption develop more slowly than expected.
- Regulatory delay or failure for new product launchesImpact: HighLikelihood: Medium
Heart and liver technologies require clinical studies and market approvals before broad commercialization.
Exposure: Heart and liver product pipeline
- Clinical evidence and adoption riskImpact: HighLikelihood: Low
Transplant centers require proof of safety and efficacy before changing standard practice.
Exposure: Machine perfusion and new treatment methods
- Foreign exchange volatilityImpact: MediumLikelihood: High
The company reports risk from a stronger SEK versus the USD and EUR.
Exposure: International revenue and cost base
- Product liability and claims riskImpact: MediumLikelihood: Low
Medical technology and organ recovery services can create damage and liability exposure.
Exposure: Clinical use and service operations
- Healthcare funding and procurement pressureImpact: Medium
Customer budgets and medical resource availability affect purchasing and service uptake.
Exposure
Accounting
Judgemental itemsThe group carries significant goodwill tied to acquired businesses and must test it for impairment.
Impact: Could materially affect balance sheet and earnings if expected cash flows weaken
Development spending is capitalized when criteria are met, then tested for recoverability.
Impact: Affects intangible assets, amortization, and impairment risk
The company sells consumables, equipment, recovery services, and FlowHawk subscriptions with different timing profiles.
Impact: Affects quarterly comparability and recurring revenue visibility
Transplant volumes are only marginally seasonal, but product mix and study revenue can move quarterly results.
Impact: Can create volatility in reported sales and margins
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026